Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA combination product hearing

Executive Summary

FDA will hold a public hearing Nov. 25 to discuss the assignment, premarket review and postmarket regulation of combination products. The meeting will be at the DoubleTree Hotel in Rockville, Md. Event will have broader scope than June 24 hearing, which addressed jurisdiction for wound healing products with live cellular components (1"The Pink Sheet" July 1, p. 15)...
Advertisement

Related Content

Cell-Based Combos Should Go Through CBER For Non-Wound Uses – PhRMA
Cell-Based Combos Should Go Through CBER For Non-Wound Uses – PhRMA
Advertisement
UsernamePublicRestriction

Register

PS040683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel